These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 15353425)

  • 21. Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction.
    Sanders GD; Hlatky MA; Every NR; McDonald KM; Heidenreich PA; Parsons LS; Owens DK
    Ann Intern Med; 2001 Nov; 135(10):870-83. PubMed ID: 11712877
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of battery longevity on costs and health outcomes associated with cardiac implantable electronic devices: a Markov model-based Monte Carlo simulation.
    Schmier JK; Lau EC; Patel JD; Klenk JA; Greenspon AJ
    J Interv Card Electrophysiol; 2017 Nov; 50(2):149-158. PubMed ID: 29110166
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of extending device longevity on the long-term costs of implantable cardioverter-defibrillator therapy: a modelling study with a 15-year time horizon.
    Boriani G; Braunschweig F; Deharo JC; Leyva F; Lubinski A; Lazzaro C
    Europace; 2013 Oct; 15(10):1453-62. PubMed ID: 23696624
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of cardiac resynchronization therapy: perspective from Argentina.
    Poggio R; Augustovsky F; Caporale J; Irazola V; Miriuka S
    Int J Technol Assess Health Care; 2012 Oct; 28(4):429-35. PubMed ID: 23006489
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Economic implications and cost-effectiveness of implantable cardioverter defibrillator and cardiac resynchronization therapy.
    Bernard ML; Gold MR
    Heart Fail Clin; 2011 Apr; 7(2):241-50, ix. PubMed ID: 21439502
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Newborn screening by tandem mass spectrometry for medium-chain Acyl-CoA dehydrogenase deficiency: a cost-effectiveness analysis.
    Venditti LN; Venditti CP; Berry GT; Kaplan PB; Kaye EM; Glick H; Stanley CA
    Pediatrics; 2003 Nov; 112(5):1005-15. PubMed ID: 14595039
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone.
    Schleinitz MD; Heidenreich PA
    Ann Intern Med; 2005 Feb; 142(4):251-9. PubMed ID: 15710958
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-Effectiveness of Left Ventricular Assist Devices in Ambulatory Patients With Advanced Heart Failure.
    Baras Shreibati J; Goldhaber-Fiebert JD; Banerjee D; Owens DK; Hlatky MA
    JACC Heart Fail; 2017 Feb; 5(2):110-119. PubMed ID: 28017351
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systematic review: cardiac resynchronization in patients with symptomatic heart failure.
    McAlister FA; Ezekowitz JA; Wiebe N; Rowe B; Spooner C; Crumley E; Hartling L; Klassen T; Abraham W
    Ann Intern Med; 2004 Sep; 141(5):381-90. PubMed ID: 15353430
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Economic Evaluation of Left Ventricular Assist Devices for Patients With End Stage Heart Failure Who Are Ineligible for Cardiac Transplantation.
    Chew DS; Manns B; Miller RJH; Sharma N; Exner DV
    Can J Cardiol; 2017 Oct; 33(10):1283-1291. PubMed ID: 28941608
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimisation of cardiac resynchronisation therapy device selection guided by cardiac magnetic resonance imaging: Cost-effectiveness analysis.
    Crespo C; Linhart M; Acosta J; Soto-Iglesias D; Martínez M; Jáuregui B; Mira Á; Restovic G; Sagarra J; Auricchio A; Fahn B; Boltyenkov A; Lasalvia L; Sampietro-Colom L; Berruezo A
    Eur J Prev Cardiol; 2020 Apr; 27(6):622-632. PubMed ID: 31487998
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of a microvolt T-wave alternans screening strategy for implantable cardioverter-defibrillator placement in the MADIT-II-eligible population.
    Chan PS; Stein K; Chow T; Fendrick M; Bigger JT; Vijan S
    J Am Coll Cardiol; 2006 Jul; 48(1):112-21. PubMed ID: 16814657
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of supervised exercise therapy in heart failure patients.
    Kühr EM; Ribeiro RA; Rohde LE; Polanczyk CA
    Value Health; 2011; 14(5 Suppl 1):S100-7. PubMed ID: 21839879
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical and economic implications of the Multicenter Automatic Defibrillator Implantation Trial-II.
    Al-Khatib SM; Anstrom KJ; Eisenstein EL; Peterson ED; Jollis JG; Mark DB; Li Y; O'Connor CM; Shaw LK; Califf RM
    Ann Intern Med; 2005 Apr; 142(8):593-600. PubMed ID: 15838065
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Economic impact of cardiac resynchronization therapy in patients with heart failure. Available evidence and evaluation of the CRT-Eucomed model for analysis of cost-effectiveness].
    Fattore G; Landolina M; Bontempi L; Cacciatore G; Curnis A; Gulizia M; Padeletti L; Mazzei L; Tavazzi L;
    Ital Heart J Suppl; 2005 Dec; 6(12):796-803. PubMed ID: 16444923
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-Effectiveness of an Antibacterial Envelope for Cardiac Implantable Electronic Device Infection Prevention in the US Healthcare System From the WRAP-IT Trial.
    Wilkoff BL; Boriani G; Mittal S; Poole JE; Kennergren C; Corey GR; Krahn AD; Schloss EJ; Gallastegui JL; Pickett RA; Evonich RF; Roark SF; Sorrentino DM; Sholevar DP; Cronin EM; Berman BJ; Riggio DW; Khan HH; Silver MT; Collier J; Eldadah Z; Holbrook R; Lande JD; Lexcen DR; Seshadri S; Tarakji KG
    Circ Arrhythm Electrophysiol; 2020 Oct; 13(10):e008503. PubMed ID: 32915063
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost effectiveness of cardiac resynchronization therapy in Greece: an analysis based on the CArdiac REsychronization in Heart Failure trial.
    Maniadakis N; Ekman M; Calvert MJ; Freemantle N; Karamalis M; Vardas P
    Europace; 2011 Nov; 13(11):1597-603. PubMed ID: 21821852
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Moderate exercise training improves functional capacity, quality of life, and endothelium-dependent vasodilation in chronic heart failure patients with implantable cardioverter defibrillators and cardiac resynchronization therapy.
    Belardinelli R; Capestro F; Misiani A; Scipione P; Georgiou D
    Eur J Cardiovasc Prev Rehabil; 2006 Oct; 13(5):818-25. PubMed ID: 17001224
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease.
    Spencer M; Briggs AH; Grossman RF; Rance L
    Pharmacoeconomics; 2005; 23(6):619-37. PubMed ID: 15960557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of cardiac resynchronization therapy in patients with heart failure: the perspective of a middle-income country's public health system.
    Bertoldi EG; Rohde LE; Zimerman LI; Pimentel M; Polanczyk CA
    Int J Cardiol; 2013 Mar; 163(3):309-315. PubMed ID: 21704396
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.